title: [The trend of new drug development for the treatment of diabetes mellitus].
abstract: The trend of new drug development in the field of diabetes mellitus is overviewed. The hypoglycemic drugs such as glucagon receptor antagonists, glucokinase activators, and GPR agonists and oral medication of GLP-1 receptor agonist are under phase 2 trial in Japan. As for therapeutic medicines for diabetic nephropathy, atrasentan as an endothelin A receptor antagonist is in phase 3 trial, and bardoxolone methyl as Nrf2 activator in phase 2 in Japan. Canagliflozin, a SGLT2 inhibitor, is in phase 3 study to obtain new indication of diabetic nephropathy. An environment surrounding development of therapeutic medicines for diabetes has been tough since FDA guidance in 2008.
authors.forename: Kohei
authors.initials: K
authors.lastname: Kaku
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology; D002986:Clinical Trials as Topic; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy*; D055808:Drug Discovery; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D018027:Receptors, Glucagon / Q000037:antagonists & inhibitors
chemical_list: D007004:Hypoglycemic Agents; D018027:Receptors, Glucagon